Negara: Afrika Selatan
Bahasa: Inggris
Sumber: South African Health Products Regulatory Authority (SAHPRA)
Lennon
A-LENNON FLUOXETINE (capsule) SCHEDULING STATUS: S5 PROPRIETARY NAME (and dosage form): A-LENNON FLUOXETINE (capsule) COMPOSITION: Each capsule contains fluoxetine hydrochloride equivalent to fluoxetine 20 mg. PHARMACOLOGICAL CLASSIFICATION: A 1.2 Psychoanaleptics (antidepressants) PHARMACOLOGICAL ACTION: Fluoxetine inhibits the neuronal uptake of serotonin into the central nervous system. Pharmacokinetics: Fluoxetine is readily absorbed from the gastro-intestinal tract with peak plasma concentrations appearing about 6 to 8 hours after administration. Fluoxetine is widely distributed throughout the body and is extensively bound to plasma proteins. Fluoxetine has a long elimination half-life of 2 to 3 days and 7 to 9 days for its major active metabolite, Norfluoxetine; changes in dose will not be fully reflected in plasma far several weeks (approximately 4 half-lives). This must be taken into account when doses are titrated or when treatment is stopped. INDICATIONS: Major depressive episodes,i.e. single episode and recurrent depression with associated anxiety. Bulimia nervosa; A- LENNON FLUOXETINE has been shown to significantly decrease binge-eating and purging activity. Obsessive-compulsive disorder:A-LENNON FLUOXETINE is indicated far the treatment of obsessive-compulsive disorder. The obsessions or compulsions must be experienced as intrusive, markedly distressing, time consuming or interfering significantly with the person's social or occupational functioning. CONTRA-INDICATIONS: Hypersensitivity to fluoxetine or other serotonin re-uptake inhibitors. Severe renal failure (glomerular filtration rate <10 mL per minute). Mono-amine oxidase inhibitors: A-LENNON FLUOXETINE should not be used concomitantly with mono-amine oxidase inhibitors. There have been reports of serious, sometimes fatal, reactions (inclu Baca dokumen lengkapnya